Publications by authors named "Saktimayee M Roy"

Claim this Profile
D
Drug Development.
Linda Jo Van Eldik, Saktimayee M Roy, Ottavio Arancio, D Martin Watterson

Alzheimers Dement· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimized 5-HT inhibitors for neuropsychiatric syndromes with cognitive dysfunction.
Saktimayee M Roy, Erica Acquarone, Elentina K Argyrousi, Hong Zhang, Agnieszka Staniszewski

Alzheimers Dement (N Y)· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A small molecule p38α MAPK inhibitor, MW150, attenuates behavioral deficits and neuronal dysfunction in a mouse model of mixed amyloid and vascular pathologies.
Hilaree N Frazier, David J Braun, Caleb S Bailey, Meggie J Coleman, Verda A Davis, Saktimayee M Roy

Brain Behav Immun Health· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The 5HT2b Receptor in Alzheimer's Disease: Increased Levels in Patient Brains and Antagonist Attenuation of Amyloid and Tau Induced Dysfunction.
Erica Acquarone, Elentina K Argyrousi, Ottavio Arancio, D Martin Watterson, Saktimayee M Roy

J Alzheimers Dis· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Therapeutic treatment with the anti-inflammatory drug candidate MW151 may partially reduce memory impairment and normalizes hippocampal metabolic markers in a mouse model of comorbid amyloid and vascular pathology.
David J Braun, David K Powell, Christopher J McLouth, Saktimayee M Roy, D Martin Watterson

PLoS One· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-in-Human Studies of MW01-6-189WH, a Brain-Penetrant, Antineuroinflammatory Small-Molecule Drug Candidate: Phase 1 Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Studies in Healthy Adult Volunteers.
Linda J Van Eldik, Lumy Sawaki, Karen Bowen, Daniel T Laskowitz, Robert J Noveck, Saktimayee M Roy

Clin Pharmacol Drug Dev· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to "A Selective and Brain Penetrant p38αMAPK Inhibitor Candidate for Neurologic and Neuropsychiatric Disorders That Attenuates Neuroinflammation and Cognitive Dysfunction".
Saktimayee M Roy, George Minasov, Ottavio Arancio, Laura W Chico, Linda J Van Eldik

J Med Chem· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Selective and Brain Penetrant p38αMAPK Inhibitor Candidate for Neurologic and Neuropsychiatric Disorders That Attenuates Neuroinflammation and Cognitive Dysfunction.
Saktimayee M Roy, George Minasov, Ottavio Arancio, Laura W Chico, Linda J Van Eldik

J Med Chem· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of Protein Kinase Inhibitors with PLK4 Cross-Over Potential in a Pre-Clinical Model of Cancer.
Amreena Suri, Anders W Bailey, Maurício T Tavares, Hendra Gunosewoyo, Connor P Dyer, Saktimayee M Roy

Int J Mol Sci· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Retention of normal glia function by an isoform-selective protein kinase inhibitor drug candidate that modulates cytokine production and cognitive outcomes.
Zhengqiu Zhou, Adam D Bachstetter, Claudia B Späni, Saktimayee M Roy, D Martin Watterson

J Neuroinflammation· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Selective suppression of the α isoform of p38 MAPK rescues late-stage tau pathology.
Nicole Maphis, Shanya Jiang, Guixiang Xu, Olga N Kokiko-Cochran, Saktimayee M Roy

Alzheimers Res Ther· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of Novel In Vivo Chemical Probes to Address CNS Protein Kinase Involvement in Synaptic Dysfunction.
D Martin Watterson, Valerie L Grum-Tokars, Saktimayee M Roy, James P Schavocky, Brinda Desai Bradaric

PLoS One· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting human central nervous system protein kinases: An isoform selective p38αMAPK inhibitor that attenuates disease progression in Alzheimer's disease mouse models.
Saktimayee M Roy, Valerie L Grum-Tokars, James P Schavocky, Faisal Saeed, Agnieszka Staniszewski

ACS Chem Neurosci· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular properties and CYP2D6 substrates: central nervous system therapeutics case study and pattern analysis of a substrate database.
Laura K Chico, Heather A Behanna, Wenhui Hu, Guifa Zhong, Saktimayee Mitra Roy

Drug Metab Dispos· November 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A novel p38 alpha MAPK inhibitor suppresses brain proinflammatory cytokine up-regulation and attenuates synaptic dysfunction and behavioral deficits in an Alzheimer's disease mouse model.
Lenka Munoz, Hantamalala Ralay Ranaivo, Saktimayee M Roy, Wenhui Hu, Jeffrey M Craft

J Neuroinflammation· September 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of a novel therapeutic suppressor of brain proinflammatory cytokine up-regulation that attenuates synaptic dysfunction and behavioral deficits.
Wenhui Hu, Hantamalala Ralay Ranaivo, Saktimayee M Roy, Heather A Behanna, Laura K Wing

Bioorg Med Chem Lett· January 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis